Shortly after Pfizer and Allergan last week announced they'd be joining hands, the market "seemed pretty skeptical," in the words of Jim Cramer, host of CNBC 's "Mad Money." Since then, Allergan's stock has rebounded--but the way Nomura analyst Shibani Malhotra sees it, investors still aren't wrapping their heads around the deal's potential long-term value.
Spanish drugmaker Almirall, moving on from its former focus on respiratory therapies, is beefing up its dermatology pipeline with a buyout of Switzerland's Poli Group.
Just a couple of weeks ago, Sanofi announced that it was mulling options for its animal health unit, Merial, which offered "limited synergies" with the rest of the company. Now, investment bankers at Lazard are running the numbers on a sale or spinoff that could value the unit at up to €12 billion, or about $12.7 billion.
Back in August, retail chain Petco filed for an initial public offering, emphasizing its newfound focus on animal health. But on November 23, the company said that it will instead be acquired for $4.6 billion by the private equity firms CVC Capital Partners and the Canadian Pension Plan Investment Board.
Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up against its former target if it wants to pursue a replacement buy.
Last month, Shire said it still believed an acquisition for Baxalta--a target that rejected it almost four months back--would make a "highly strategic combination." And now, it's preparing to follow up.
Pfizer may be amped about its brand-new agreement to tie up with Allergan and move to tax-advantaged Ireland. But U.S. politicians? They're not so thrilled with the idea.
Synerlab, a French pharmaceutical manufacturer, has purchased Spain-based contract development and manufacturing company Alcala Farma for an undisclosed amount.
Both Pfizer and Allergan have a history of doing "transformational" deals--and those can come along with serious layoffs. So now that they've joined hands in a $160 billion merger agreement, is there reason to expect any different?
After finally turning back the long-running takeover attempt by Mylan, Perrigo assured shareholders they could expect "industry-leading future growth prospects." In its first move toward delivering on that promise, the OTC specialist said today it will buy the U.S. rights to AstraZeneca's Crohn's disease drug Entocort.